Table 1 Clinical and histopathological characteristics of the screening cohort and the validation cohort
Clinical variable | Screening cohort (FF) | Validation cohort (FFPE) |
|---|---|---|
Total number of cancer samples | 36 | 163 |
Age median(range) Years | 63 (46–71) | 62(48–72) |
Gleason grade | ||
Low (5–6) | 17 (47%) | 60 (37%) |
Intermediate (7) | 15 (42%) | 85 (52%) |
High (8–10) | 4 (11%) | 18 (11%) |
Pathological stage | ||
T2a-c | 19 (53%) | 96 (59%) |
T3a-b | 17 (47%) | 67 (41%) |
Time to recurrence (range) Months | 15.6 (1–74) | 24 (3–122) |
Follow up non-recurrent cases Months | 66 (31–80) | 65 (48–114) |
Recurrence | ||
Yes | 22 (61%) | 96 (59%) |
No | 14 (39%) | 67 (41%) |
Margin status | ||
Positive | 16 (44%) | 45 (28%) |
Negative | 20 (56%) | 118 (72%) |
Pre-operative PSA (range) | 16.0 (5.3-42.5) | 13.2 (2.1-64.5) |